Dexcom INC Form 4 insider transactions

Director Renee D Gala acquired 5,720 shares of Dexcom Inc. common stock on March 6, 2025, through a grant of restricted stock units.

Dexcom's EVP and Chief Financial Officer, Jereme M. Sylvain, reported the vesting of performance stock units and subsequent sale of shares to cover tax obligations.

Dexcom's EVP, Matthew Dolan, acquired shares through vested performance stock units and sold a portion to cover tax obligations.

Dexcom's EVP, Chief HR Officer, Sadie Stern, sold 2,093 shares to cover tax obligations after 5,586 performance stock units vested.

Dexcom's EVP, Chief Operating Officer, Jacob Steven Leach, sold 2,634 shares to cover tax obligations after performance stock units vested.

Dexcom's CEO, Kevin Sayer, acquired 68,503 shares of common stock through the vesting of performance stock units and subsequently sold 33,359 shares to cover tax obligations.

Dexcom's Executive Vice President and Chief HR Officer, Sadie Stern, sold 424 shares of common stock to cover tax obligations related to vesting restricted stock units.

Dexcom's Chief Financial Officer, Jereme M. Sylvain, sold 744 shares of common stock to cover tax obligations related to the vesting of restricted stock units.

Dexcom's EVP, Chief Operating Officer, Jacob Steven Leach, sold 744 shares of common stock to cover tax obligations related to vesting restricted stock units.

Dexcom director Bridgette P. Heller sold 1,000 shares of common stock at $76.87 per share on December 16, 2024, under a pre-arranged 10b5-1 trading plan.

Dexcom's EVP, Chief HR Officer, Sadie Stern, sold 4,259 shares of common stock to cover tax obligations related to vesting restricted stock units.

Dexcom's Chief Financial Officer, Jereme M. Sylvain, sold 3,500 shares of common stock at $75.51 per share under a pre-arranged 10b5-1 trading plan.

Dexcom Inc. Director Bridgette P. Heller sold 1,000 shares of common stock at $70 per share on September 16, 2024, under a pre-arranged 10b5-1 trading plan.

Sadie Stern, EVP and Chief HR Officer of Dexcom Inc., sold 426 shares of common stock on September 9, 2024, to cover tax withholding obligations related to vesting RSUs.

Jereme M. Sylvain, EVP and Chief Financial Officer of Dexcom Inc., sold 746 shares of common stock to cover tax withholding obligations related to the vesting of restricted stock units.

Dexcom's EVP, Chief Operating Officer, Jacob Steven Leach, sold 746 shares of common stock on September 9, 2024, to cover tax withholding obligations related to vesting RSUs.

Michael Brown, EVP and Chief Legal Officer of Dexcom Inc., sold 686 shares of common stock at $70 per share on August 30, 2024, under a pre-arranged 10b5-1 trading plan.

EVP and Chief Legal Officer of Dexcom, Michael Jon Brown, sold 652 shares of common stock at $69.55 per share on July 31, 2024, under a pre-arranged 10b5-1 trading plan.

EVP and Chief Legal Officer of Dexcom Inc., Michael Jon Brown, sold 659 shares of common stock at $114.29 per share on June 28, 2024, under a pre-arranged 10b5-1 trading plan.

Director Mark G. Foletta sold Dexcom Inc. shares on June 17 and 18, 2024, under a pre-arranged 10b5-1 trading plan.

Bridgette P Heller, a director at DexCom Inc, sold 1,000 shares of common stock on June 14, 2024, under a pre-arranged 10b5-1 trading plan.

Executive Vice President and Chief Financial Officer of Dexcom, Jereme Sylvain, sold 745 shares of common stock on June 10, 2024, to cover tax withholding obligations related to the vesting of restricted stock units.

Sadie Stern, EVP and Chief HR Officer of Dexcom Inc., sold 427 shares of common stock on June 10, 2024, to cover tax withholding obligations related to vesting restricted stock units.

Dexcom's Executive Vice President and Chief Operating Officer, Jacob Steven Leach, reported selling shares to cover tax withholding obligations related to vesting restricted stock units.

Michael Brown, EVP and Chief Legal Officer of Dexcom Inc., sold 652 shares of common stock at $119.24 per share on May 31, 2024, under a pre-arranged 10b5-1 trading plan.

Director Eric Topol acquired 2,618 shares of Dexcom Inc. common stock on May 22, 2024, through a restricted stock unit (RSU) award.

Director Kyle Malady reports acquisition of 2,613 shares of Dexcom Inc. common stock through a restricted stock unit (RSU) award.

Director Bridgette P Heller acquired 2,618 shares of DexCom Inc. common stock on May 22, 2024, through a restricted stock unit (RSU) award.

Director Mark G Foletta received 2,973 shares of DexCom stock on May 22, 2024, as part of a restricted stock unit (RSU) award.

Director Rimma Driscoll reports the acquisition of 2,632 shares of DexCom stock through a restricted stock unit (RSU) award.